Ideaya Biosciences (IDYA) announced development candidate nomination of IDE892, a MTA-cooperative PMRT5 inhibitor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences initiated with an Overweight at Stephens
- Ideaya Biosciences appoints Stu Dorman as chief commercial officer
- Ideaya Biosciences nominates IDE034 as development candidate, exercises option
- Biocytogen announces Ideaya’s nomination of development candidate IDE034
- Dollar Tree downgraded, eBay upgraded: Wall Street’s top analyst calls